A Breakthrough: Defining Plasmodium vivax Drug Resistance Genes
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiac470 ↗Kurz gefasst
Editorial in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Carol Hopkins Sibley. Beteiligte Einrichtung: Department of Genome Sciences, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Plasmodium cynomolgi, Antimalarials, Malaria, Vivax. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Plasmodium falciparum is currently the best known and most studied human malaria parasite; the World Health Organization Global Malaria Program estimates that in 2020 malaria caused 667 000 deaths and extensive morbidity, most attributed to P. falciparum [1]. However, P. falciparum is not the only malaria parasite with a major impact on the human population. Plasmodium vivax remains a major cause of disease and death in Asia, Latin America, and Oceania [2, 3], but despite its importance, detailed laboratory-based studies of P. vivax have lagged far behind those of P. falciparum. This disparity between the number of P. falciparum and P. vivax studies can be partly explained by technology. In 1976, William Trager and James Jensen published methods that allowed cloning and sustained in vitro culture of the erythrocytic phase of P. falciparum [4]. The malaria research community responded with enthusiasm to the Trager-Jensen breakthrough and developed a large and sophisticated portfolio of laboratory-based methods for cloning individual parasites and exploring the genetic basis for parasite phenotypes in P. falciparum [5]. In particular, methods were rapidly adapted to test the susceptibility of cloned P. falciparum lines to chloroquine (CQ) and identify mutations causally related to CQ resistance (see Fidock et al [6], for example). Molecular surveillance for parasites that carried these molecular markers could then quickly identify P. falciparum populations that carried the CQ resistance marker [7, 8]. In contrast, despite heroic efforts by many researchers, only short-term measurements of antimalarial susceptibility were possible for P. vivax [9, 10], so many of the P. falciparum methods were not available to resolve similar questions for P. vivax. At the same time, field studies made it clear that the clinical efficacy of CQ against P. vivax was already diminishing in some regions [11], with serious consequences for both morbidity and mortality rates associated P. vivax [2]. There was clearly an urgent need to establish whether any of the genes associated with CQ resistance in P. falciparum might also confer a CQ resistance phenotype in P. vivax. Without sustained, cloned lines of P. vivax to test, an alternative approach was needed. As a first step, Ward et al [12], reporting in the current issue of The Journal of Infectious Diseases, established a long-term culture system and protocols to test the effect of mutations that may confer CQ resistance in Plasmodium cynomolgi, a malaria parasite that infects Macaques in Southeast Asia [13]. In support of this approach, the authors point out that the biologic and morphologic features of P. cynomolgi and P. vivax are virtually indistinguishable in the erythrocytic stage [14]. Even better, genomic comparisons showed that, phylogenetically, the 2 species are extremely close relatives [15]. This information stimulated a long and ultimately successful collaborative effort to clone and adapt P. cynomolgi to continuous culture and establish methods to genetically engineer the cultured P. cynomolgi lines. To test the system, Ward et al [12] adapted well-established P. falciparum protocols, using CRISPR Cas 9 technology to create the P. vivax CQ mutation in the pcmdr1 orthologue of their cloned and cultured P. cynomolgi line [5]. Using adaptations of the standard protocols routinely used to test cultured P. falciparum lines for drug response in the laboratory [16], they then tested the susceptibility of these mutant P. cynomolgi parasites to a battery of standard antimalarials, including CQ, amodiaquine, piperaquine, and mefloquine, all antimalarials whose transport depends on the P. falciparum multidrug resistance 1 (PfMDR1) transporter. The data presented by Ward et al [12] demonstrate that their approach worked, but there was a surprise. Clones from P. cynomolgi that were engineered to carry the mutation from the P. vivax gene in question were not resistant to CQ. However, although the unmodified controlP. cynomolgi line was highly resistant to mefloquine, the P. cynomolgi clones carrying the P. vivax mutant allele were, unexpectedly, highly susceptible to mefloquine [17]. In addition, another recent publication testing the role of PfMDR1 mutant proteins in transport of these antimalarials in Xenopus oocytes reported similar results [18]. Ward et al [12] define a novel path for identifying molecular markers of antimalarial resistance in P. vivax. However, the significance goes far beyond antimalarial resistance. The availability of the cloned P. cynomolgi lines and detailed protocols for implementation of genetic engineering can, and certainly will, be applied to many other questions that remain unanswered for P. vivax. The authors note that this path will not be easy; they point out that establishing this new system took a several-years-long, collaborative process among highly experienced laboratories. However, there is every reason to anticipate many rewards if the P. cynomolgi system can be further adapted to answer the many outstanding questions about P. vivax. Further progress is certainly required if P. vivax is to be better controlled and finally eliminated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genome Sciences, University of Washington, Seattle, Washington, USA.
Zitieren
APA
Sibley, C. H. (2023). A Breakthrough: Defining Plasmodium vivax Drug Resistance Genes. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac470
Vancouver
Sibley CH. A Breakthrough: Defining Plasmodium vivax Drug Resistance Genes. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac470
BibTeX
@article{Sibley2023,
author = {Sibley, Carol Hopkins},
title = {A Breakthrough: Defining Plasmodium vivax Drug Resistance Genes},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiac470}
}
EUVIMED